nect Biopharma (CNTB) - 2025 Q2 - Quarterly Report

TABLE OF CONTENTS FORM 10-Q _______________________ x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _______________________ For the transition period from _______ to ________ Commission File Number: 001-40212 Connect Biopharma Holdings Limited (Exact name of ...